Several studies have demonstrated that the combination of STAT inhibitors with radiotherapy [207,208,209], chemotherapy [210], anti-CTLA-4 and anti-PD-L1 ICIs [211,212], and anti-EGFR therapies like cetuximab [213] can improve tumour response and ameliorate resistance. This evidence concerns the gene SOAT1 and neoplasm.